| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2021-02-10 | RA CAPITAL MANAGEMENT, L.P. | Keros Therapeutics, Inc. | 1,875,000 | 8.1% | EDGAR |
| SC 13G/A | 2021-02-08 | FMR LLC | Keros Therapeutics, Inc. | 2,644,620 | 11.4% | EDGAR |
| SC 13G | 2021-02-02 | BlackRock Inc. | Keros Therapeutics, Inc. | 1,199,201 | 5.2% | EDGAR |
| SC 13D/A | 2020-12-17 | Arkin Moshe | Keros Therapeutics, Inc. | 2,013,102 | 8.7% | EDGAR |
| SC 13D/A | 2020-11-25 | Arkin Moshe | Keros Therapeutics, Inc. | 2,013,102 | 8.7% | EDGAR |
| SC 13D/A | 2020-11-20 | ORBIMED ADVISORS LLC | Keros Therapeutics, Inc. | 1,268,734 | 5.5% | EDGAR |
| SC 13G | 2020-11-10 | FMR LLC | Keros Therapeutics, Inc. | 3,025,881 | 15.0% | EDGAR |
| SC 13G | 2020-08-31 | Logos Global Management LP | Keros Therapeutics, Inc. | 1,350,000 | 6.7% | EDGAR |
| SC 13D | 2020-04-23 | Pontifax Management 4 G.P. (2015) Ltd. | Keros Therapeutics, Inc. | 4,734,507 | 23.6% | EDGAR |
| SC 13D | 2020-04-20 | Arkin Moshe | Keros Therapeutics, Inc. | 2,013,102 | 10.5% | EDGAR |
| SC 13D | 2020-04-17 | ORBIMED ADVISORS LLC | Keros Therapeutics, Inc. | 1,268,734 | 6.3% | EDGAR |
| SC 13G | 2020-04-15 | Foresite Capital Fund IV, L.P. | Keros Therapeutics, Inc. | 1,428,071 | 7.1% | EDGAR |